Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.
Hsiu-Jung TungRen-Chin WuChiao Yun LinChyong-Huey LaiPublished in: International journal of molecular sciences (2022)
Endometrial cancer (EC) is one of the most common gynecologic cancers worldwide. There were 417,367 newly diagnosed cases and 97,370 deaths due to this disease worldwide in 2020. The incidence rates have increased over time, especially in countries with rapid socioeconomic transitions, and EC has been the most prevalent gynecologic malignancy in Taiwan since 2012. The new EC molecular classifications of The Cancer Genome Atlas (TCGA) Research Network include clear-cell carcinoma, serous carcinoma, and carcinosarcoma, while undifferentiated/dedifferentiated EC (UDEC) is not mentioned, and most previous clinical trials for EC have not included UDEC. UDEC is rare, has an aggressive growth pattern, tends to be diagnosed at an advanced stage, and is resistant to conventional chemotherapy. In this review, case series or case reports on the clinical features and genomic/epigenetic and expression profiles on UDEC data are summarized in order to identify potential molecular targets for current and future research.
Keyphrases
- endometrial cancer
- newly diagnosed
- clinical trial
- clinical practice
- genome wide
- gene expression
- high grade
- copy number
- dna methylation
- papillary thyroid
- risk factors
- case report
- squamous cell carcinoma
- single cell
- electronic health record
- radiation therapy
- randomized controlled trial
- locally advanced
- machine learning
- young adults
- climate change
- current status
- artificial intelligence
- deep learning